☆ 4.4 Article

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Allergy

The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti-IL-5 Biologic Therapy

Claus Bachert et al.

Summary: The unified airway hypothesis suggests that upper and lower airway diseases are part of a single pathological process. Recent studies have shown the important role of eosinophils and IL-5 in these diseases, although their impact may vary. Targeting eosinophils and IL-5 with pharmaceuticals has shown clinical benefits, supporting the hypothesis that these conditions are linked and manifest in different locations.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

添加到收藏夹

Article Allergy

Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count

Claus Bachert et al.

Summary: Mepolizumab demonstrates efficacy in reducing nasal polyp size and nasal obstruction in patients with chronic rhinosinusitis with nasal polyps, regardless of comorbid asthma or aspirin-exacerbated respiratory disease.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Article Respiratory System

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

Wendy C. Moore et al.

Summary: This study examined the clinical impact of stopping long-term use of mepolizumab for severe eosinophilic asthma. The results showed that patients who stopped mepolizumab had increased exacerbations and reduced asthma control compared to those who continued treatment.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹

Article Allergy

Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study

Philippe Gevaert et al.

Summary: This study confirms the sustained efficacy and safety of omalizumab treatment for chronic rhinosinusitis with nasal polyps for up to one year, which is of significant importance for patients who do not respond to nasal corticosteroids.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Article Allergy

Factors leading to discontinuation of biologic therapy in patients with severe asthma

Jared Silver et al.

Summary: This study investigated the main reasons for discontinuing biologic therapy among patients with severe asthma and found that the most common reasons were lack of symptom control, exacerbations, cost, and patient request. The data highlight the complexity of treatment challenges faced by these patients and the importance of regular assessment of biologic therapy continuation and discontinuation.

JOURNAL OF ASTHMA (2022)

添加到收藏夹

Article Allergy

Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial

Claus Bachert et al.

Summary: This study assessed the efficacy and safety of benralizumab in treating CRSwNP. The results showed that benralizumab significantly improved NPS and nasal blockage score, and had significant improvement on difficulty with sense of smell score. Subgroup analyses suggested influences of comorbid asthma, number of NP surgeries, sex, body mass index, and baseline blood eosinophil count on treatment effects.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Article Allergy

EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management

Claus Bachert et al.

Summary: Uncontrolled severe CRSwNP can be challenging due to its association with asthma, NSAID-exacerbated respiratory disease, and allergies. The European Forum proposes structured definitions to facilitate communication among clinicians and offers a practical algorithm for defining type 2 inflammation in CRSwNP. Suggestions for evaluating treatment options, including surgery and biologics, are provided to inform patients for decision-making processes.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

Joseph K. Han et al.

Summary: The study aimed to evaluate the efficacy and safety of mepolizumab in adults with recurrent, refractory severe bilateral chronic rhinosinusitis with nasal polyps. Results showed that mepolizumab treatment significantly improved nasal polyp size and nasal obstruction symptoms, with fewer adverse events.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Review Allergy

Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis

Anna G. Staudacher et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)

添加到收藏夹

Article Allergy

Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin

Tetsuji Takabayashi et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Article Allergy

IL-5Rα marks nasal polyp IgG4-and IgE-expressing cells in aspirin-exacerbated respiratory disease

Kathleen M. Buchheit et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Review Allergy

Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper

Valerie Hox et al.

CLINICAL AND TRANSLATIONAL ALLERGY (2020)

添加到收藏夹

Review Allergy

EUFOREA consensus on biologics for CRSwNP with or without asthma

Wytske J. Fokkens et al.

ALLERGY (2019)

添加到收藏夹

Article Allergy

Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis

Whitney W. Stevens et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)

添加到收藏夹

Article Allergy

Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis

Lien Calus et al.

CLINICAL AND TRANSLATIONAL ALLERGY (2019)

添加到收藏夹

Letter Allergy

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Hector Ortega et al.

ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Claus Bachert et al.

LANCET (2019)

添加到收藏夹

Article Otorhinolaryngology

Systemic Predictors of Eosinophilic Chronic Rhinosinusitis

Jacqueline Ho et al.

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Prevalence of Polyp Recurrence After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis

Adam S. DeConde et al.

LARYNGOSCOPE (2017)

添加到收藏夹

Article Allergy

Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

Peter Tomassen et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

The burden of revision sinonasal surgery in the UK-data from the Chronic Rhinosinusitis Epidemiology Study (CRES): a cross-sectional study

Carl Philpott et al.

BMJ OPEN (2015)

添加到收藏夹

Letter Allergy

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis

Pranabashis Haldar et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

添加到收藏夹

Article Allergy

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis

Philippe Gevaert et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.